Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension

• Published in: The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2018-03, Vol.20 (3), p.560-567
• Main Authors: Gu, Jun, Fan, Yu‐Qi, Zhang, Hui‐Li, Zhang, Jun‐Feng, Wang, Chang‐Qian
• Format: Article
• Language: English
• Subjects: Aged; diastolic dysfunction; Echocardiography, Doppler; Female; Heart Failure - epidemiology; Heart Failure - etiology; heart failure with preserved ejection fraction; Humans; hypertension; Hypertension - blood; Hypertension - complications; Hyperuricemia - blood; Hyperuricemia - complications; Incidence; left ventricular hypertrophy; Male; Middle Aged; Original Paper; Prognosis; Retrospective Studies; Stroke Volume; Survival Analysis; uric acid; Uric Acid - blood; Uric Acid and Hypertension
• ISSN: 1524-6175; 1751-7176
• DOI: 10.1111/jch.13210

The objective of the present study was to evaluate clinical implications of serum uric acid (UA) on the progression of heart failure with preserved ejection fraction (HFpEF) in hypertensive patients. A total of 1009 adult patients with left ventricular hypertrophy and suspected left ventricular diastolic dysfunction were enrolled at our hospital from January 2008 to December 2011. With a median follow‐up of 7.2 years, 136 (13.2%) patients developed new‐onset HFpEF and 151 (15.0%) had major adverse cardiovascular events (MACEs). Compared with the lowest UA tertile of UA (367 μmol L−1) had a higher risk of developing new‐onset HFpEF (HR: 1.761, 95% CI: 1.119‐2.772, P = .015) as well as MACEs (HR: 1.664, 95% CI: 1.086‐2.547, P = .019). Our findings indicate that hyperuricemia is associated with detrimental effects in terms of the incidence of new‐onset HFpEF as well as MACEs in hypertensive patient.